Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in upcoming investor conferences.
- LEERINK Partners 6th Annual Global Healthcare Conference, February 15-16, 2017, New York
- 2017 Disruptive Growth & Healthcare Conference, February 15, 2017, New York
- RBC Capital Markets 2017 Global Healthcare Conference, February 22-23, 2017, New York
Arbutus’ President and CEO, Dr. Mark J. Murray, will participate in a fireside chat at the LEERINK conference on February 16, 2017. A simultaneous webcast can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations. Replays will be available on the Arbutus website following the event.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Senior Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
